Top

Pediatric Drugs

Published in:

01-01-2008 | Review Article

Managing Crohn Disease in Children and Adolescents

Focus on Tumor Necrosis Factor Antagonists

Authors: Shehzad A. Saeed, Dr Wallace V. Crandall

Published in: Pediatric Drugs | Issue 1/2008

Abstract

Crohn disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by a relapsing course and variable presentation that often includes abdominal pain, diarrhea, and fatigue. CD frequently presents during childhood, resulting in pediatric-specific complications, such as growth failure and delayed puberty. Conventional drug therapy for moderate to severe pediatric CD includes induction of remission with corticosteroids, and maintenance of remission with immunomodulators. Patients who have an inadequate response to standard therapy are being increasingly treated with anti-tumor necrosis factor-α (TNFα) agents. Infliximab has been the most widely studied anti-TNFα agent in pediatric CD, and has been shown to be efficacious in this condition. Adalimumab has been proven to be efficacious in adults with CD, but there has been only a single case report in children. CDP571 has been tested in 20 children with CD, showing some efficacy. Finally, thalidomide therapy has been associated with improvement in two small case series. Toxicities of these agents include infusion reactions, infections, malignancies, neurologic disorders, and hematologic derangements.

The use of trade names is for product identification purposes only and does not imply endorsement.

Barton JR, Gillon S, Ferguson A. Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three fold rise in Crohn’s disease. Gut 1989; 30: 618–22PubMedCrossRef

Langholz E, Munkholm P, Kraslinikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity and mortality in a regional cohort. Scand J Gastroenterol 1997; 32: 139–47PubMedCrossRef

Kugathasan S, Judd RH, Hoffman RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a state-wide population based study. J Pediatr 2003; 143: 525–31PubMedCrossRef

Bjornsson S, Johansson JH. Inflammatory bowel disease in Iceland, 1990–1994: a prospective, nationwide, epidemiological study. Eur J Gatroenterol Hepatol 2000; 12: 31–8CrossRef

Baldassano RN, Piccoli DA. Inflammatory bowel disease in Pediatric and adolescent patients. Gastroenterol Clin North Am 1999; 28: 445–58PubMedCrossRef

Mamula P, Markowitz JE, Baldassano RN. Inflammatory bowel disease in early childhood and adolescents: special considerations. Gastroenterol Clin North Am 2003; 32: 967–95PubMedCrossRef

Romagnani S. Thl/Th2 cells. Inflamm Bowel Dis 1999; 5: 285–94PubMedCrossRef

Sands BE. Why do anti-tumor necrosis factor antibodies work in Crohn’s disease? Rev Gastroenterol Disord 2004; 4Suppl. 3: S10–7PubMed

Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148–57PubMedCrossRef

10.

Dieu MC, Vanbervliet B, Vicari A, et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188: 373–86PubMedCrossRef

11.

Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411–52PubMedCrossRef

12.

Pender SL, Fell JM, Chamow SM, et al. A p55 TNF receptor immunoadhesion prevents T cell-mediated intestinal injury by inhibiting matrix metal-loproteinase production. J Immunol 1998; 160: 4098–103PubMed

13.

Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999; 72: 255–324PubMedCrossRef

14.

Mack DR, Young R, Kaufmann SS, et al. Methotrexate in patients with Crohn’s disease after 6-mercaptopurine. J Pediatr 1998; 132: 830–5PubMedCrossRef

15.

Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990; 117: 809–14PubMedCrossRef

16.

Kirschner B. Safety of azathioprine and 6-mercaptopurine in Pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813–21PubMedCrossRef

17.

Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late Pediatric Crohn’s disease. Am J Gastroenterol 2000; 95: 3189–94PubMedCrossRef

18.

Hommes D, Baert F, van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn’s disease (CD): ‘top down’ vs. ‘step up’ strategies [abstract no. W1017]. Digestive Diseases Week conference; 2005 May 14–19; Chicago (IL)

19.

Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn’s disease. J Pediatr Gastroenterol Nutr 2005; 40: 220–2PubMedCrossRef

20.

Scallon BJ, Moore MA, Trinh H. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995; 7: 251–9PubMedCrossRef

21.

Van den Brande JM, Braat H, VanDen Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn’s disease. Gastroenterology 2003; 124: 1774–85PubMedCrossRef

22.

Cornillie F, Shealy D, D’Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 2001; 14: 463–73CrossRef

23.

Baldassano R, Braeger CP, Escher JC, et al. Infliximab (Remicade) therapy in the treatment of Pediatric Crohn’s disease. Am J Gastroenterol 2003; 98: 833–8PubMedCrossRef

24.

Hyams JS, Markowitz J, Wylie R. Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr 2000; 137: 192–6PubMedCrossRef

25.

Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid sparing experience using infliximab for Crohn’s disease at a Pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104–11PubMedCrossRef

26.

Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn’s disease. Inflamm Bowel Dis 2004; 10: 745–50PubMedCrossRef

27.

Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1 year outcomes in newly diagnosed children with Crohn’s disease. Clin Gastroenterol Hepatol 2006; 4: 1124–9PubMedCrossRef

28.

Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factor (Remicade®) in severe Pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 2003; 36: 632–6PubMedCrossRef

29.

de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory Pediatric Crohn’s disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39: 46–52PubMedCrossRef

30.

Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 2003; 18: 425–31PubMedCrossRef

31.

Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-meracptopurine for the treatment of perianal Crohn’s disease in children. J Clin Gastroenterol 2000; 30: 294–8PubMedCrossRef

32.

Kanof M, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 1988; 95: 1523–7PubMed

33.

Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 2004; 36: 342–7PubMedCrossRef

34.

Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn’s disease. J Pediatr Gastroenterol Nutr 2006; 42: 40–5PubMedCrossRef

35.

Benkov KJ, Vorha P, Pittman NS, et al. Pathogenesis of immunological/inflammatory GI disease and IBD [abstract no. 86]. J Pediatr Gastroenterol Nutr 1996; 23: 363CrossRef

36.

Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone with newly diagnosed Crohn’s disease. Gastroenterology 2000; 119: 895–902PubMedCrossRef

37.

Steiner SJ, DiMeglio LA, Denne SC. Single dose of infliximab alters bone metabolism in Pediatric Crohn’s disease [poster]. 5th CCFA Annual Advances in Inflammatory Bowel Disease; 2006 Dec 1–3; Miami (FL)

38.

Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 2007; 132: 863–73PubMedCrossRef

39.

Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75–84PubMedCrossRef

40.

Mayer L, Young Y. Infusion reactions and their management. Gastroenterol Clinic N Am 2006, 866

41.

Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315–24PubMedCrossRef

42.

Rutgeerts P, Feagan BG, Lichtenstein G, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 402–13PubMedCrossRef

43.

Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251–8PubMedCrossRef

44.

Chang JT, Lichtenstein GR. Drug insight: antagonists of tumor necrosis factor-α in the treatment of inflammatory bowel disease. Nat Clin Pract 2006; 3: 220–8

45.

Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial. Gastroenterology 2006; 130: 323–33PubMedCrossRef

46.

Sandborn WJ, Hanauer SB, Lukas M, et al. Maintenance of remission over 1 year in patients with active Crohn’s disease treated with adalimumab: results of a blinded, placebo-controlled study [abstract no. 843]. Am J Gastroenterol 2005; 100Suppl. S: S311

47.

Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response in patients with Crohn’s disease: the CHARM Trial. Gastroenterol 2007; 132: 52–65CrossRef

48.

Sandborn WJ, Hanauer S, Loftus EV, et al. An open label study of the human antitnf monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004; 99: 1984–9PubMedCrossRef

49.

Hinojosa J, Gomollon F, Nos P, et al. Four week results of adalimumab treatment in subjects with fistulizing Crohn’s disease who have failed response or showed intolerance to infliximab [abstract no. 815]. Digestive Diseases Week; 2006 May 19–24; Los Angeles (CA)

50.

Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn’s disease. J Pediatr Gastroenterol Nutr 2005; 41(3): 357–9PubMedCrossRef

51.

Baldassano RN. Surpassing conventional therapies: the role of biologic therapy. J Pediatr Gastroenterol Nutr 2001; 33: S19–26PubMedCrossRef

52.

Kurtovic J, Segal I. Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 2004; 25: 9–14PubMed

53.

Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanized monoclonal antibody to tumor necrosis factor a, for moderate to severe Crohn’s disease: a randomized, double blind, placebo controlled trial. Gut 2004; 53: 1485–93PubMedCrossRef

54.

Mamula P, Cohen SA, Ferry GA, et al. CDP-571, a humanized anti tumor necrosis factor α monoclonal antibody in Pediatric Crohn’s disease. Inflamm Bowel Dis 2004; 10: 723–30PubMedCrossRef

55.

Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991; 173: 699–703PubMedCrossRef

56.

Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn’s disease: preliminary results. J Pediatr Gastroenterol Nutr 2001; 32: 178–81PubMedCrossRef

57.

Martelossi S, Marchetti F, Lenhardt A, et al. Treatment with thalidomide in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: S282CrossRef

58.

Schreiber S, Rutgeerts P, Fedorak R, et al. A randomized placebo-controlled trial of certolizumab pegol (CDP 870) for treatment of Crohn’s disease. Gastroenterology 2005; 129: 807–18PubMedCrossRef

59.

Schreiber S, Khaliq-Kareemi M, Lawrence I, et al. Certolizumab pegol, a humanized anti-TNF pegylated FAb’ fragment, is safe, and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study (PRECiSE). Gut 2005; 54Suppl. VII: A82

60.

Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumor necrosis factor receptor): results of a randomized, open label, pilot study. Aliment Pharmacol Ther 2003; 17: 185–92PubMedCrossRef

61.

Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate to severe Crohn’s disease: a randomized, double blind, placebo controlled trial. Clin Gastroenterol Hepatol 2006; 4: 888–93PubMedCrossRef

62.

D’Haens G, Swijsen C, Norman M, et al. Etanercept in the treatment of active refractory Crohn’s disease: a single center pilot trial. Am J Gastroenterol 2001; 96: 2564–8PubMedCrossRef

63.

Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088–94PubMedCrossRef

64.

Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn’s disease. Gastroenterology 2002; 122: 7–14PubMedCrossRef

65.

Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT Registry. Clin Gastroenterol Hepatol 2006; 4: 621–30PubMedCrossRef

66.

Remicade® (infliximab) prescribing information. Malvern (PA): Centocor Inc., 2007

67.

D’ Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007; 56: 725–32CrossRef

68.

Surveillance, Epidemiology, and End Results Database (SEER) program. SEER incidence crude rates, 11 Registries, 1993–2001. Rockville (MD): National Cancer Institute

69.

Humira® (adalimumab) prescribing information. Chicago (IL): Abbott Laboratories, 2007

70.

Remicade® (infliximab) for IV injection prescribing information. Malvern (PA): Centocor Inc., 2007

71.

Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancy. Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 296: 2275–85CrossRef

72.

Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 2007; 13(8): 1024–30PubMedCrossRef

73.

Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265–7PubMedCrossRef

Title: Managing Crohn Disease in Children and Adolescents
Focus on Tumor Necrosis Factor Antagonists
Authors: Shehzad A. Saeed
Dr Wallace V. Crandall
Publication date: 01-01-2008
Publisher: Springer International Publishing
Published in: Pediatric Drugs / Issue 1/2008
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI: https://doi.org/10.2165/00148581-200810010-00004

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Managing Crohn Disease in Children and Adolescents

Focus on Tumor Necrosis Factor Antagonists

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Dysmenorrhea in Adolescents

Clinical Uses of Dexmedetomidine in Pediatric Patients

Management of Chronic Daily Headache in Children and Adolescents

Corticosteroid-Resistant Nephrotic Syndrome with Focal and Segmental Glomerulosclerosis

Switching from Neurostimulant Therapy to Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder